Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps

Cancer Cell. 2025 Sep 8;43(9):1622-1636.e7. doi: 10.1016/j.ccell.2025.06.007. Epub 2025 Jul 3.

Abstract

Disseminated tumor cells (DTCs) can remain in a non-proliferative, dormant state for years in distant organs, but the exogenous causes triggering their reactivation and metastatic colonization are unclear. Here, we demonstrate that chemotherapeutic drugs, including doxorubicin and cisplatin, enhance proliferation and lung metastasis of dormant breast cancer cells. Using a recombinase-based dormancy tracing system, DormTracer, we confirm chemotherapy-induced reactivation of dormant DTCs leading to metastatic relapse. Mechanistically, chemotherapy induces fibroblast senescence, which promotes formation of neutrophil extracellular traps (NETs) through secreted proteins. NETs promote dormant DTC proliferation through extracellular matrix remodeling. Importantly, combining senolytic drugs, dasatinib and quercetin, with doxorubicin inhibits post-therapy DTC reactivation and suppresses metastatic relapse. This study provides direct evidence of dormancy awakening and reveals a mechanism underlying detrimental effect of chemotherapy on metastasis, highlighting potential strategies to improve cancer treatment.

Keywords: chemotherapy; dormancy awakening; metastatic dormancy; neutrophil extracellular trap.

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / pathology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cisplatin / pharmacology
  • Doxorubicin / pharmacology
  • Extracellular Traps* / drug effects
  • Extracellular Traps* / metabolism
  • Female
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / pathology
  • Lung Neoplasms* / secondary
  • Mice
  • Neutrophils* / drug effects
  • Neutrophils* / metabolism
  • Xenograft Model Antitumor Assays

Substances

  • Doxorubicin
  • Cisplatin
  • Antineoplastic Agents